and Objective: The objective of this Prospective Registry was to prospectively assess the oncologic, functional and safety outcomes of salvage HIFU in radio-recurrent prostate cancer (rrPCa).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Eighty one men were prospectively recruited and evaluated at regular scheduled study visits to 6 months post-HIFU and thereafter as per standard of care. Transrectal ultrasound guided biopsy (TRUS Bx) was performed at 6 months. Primary endpoint was absence or histologic persistence of disease at 6 months Bx. Secondary endpoints included QoL, biochemical recurrence-free survival (BRFS), overall survival (OS), cancer specific survival (CSS) and progression to androgen deprivation therapy (ADT). Survival analysis was carried out according to Kaplan-Meier's method and multivariate analysis was performed using the log-rank (Mantel-Cox) test.
The mean pre-HIFU PSA was 4.06 ± 2.88 ng/mL. At 6 months, 63 men underwent Bx, of which 22 (35%) were found to have residual disease. With a mean follow-up of 53.5 ±31.6 months, the median BRFS was 63 months. The 5-year OS and CSS were 88% and 94.4% respectively. Nadir PSA of <0.5ng/mL was a significant predictor (p=0.014, 95% CI 1.22-5.87) of BRFS. IPSS scores significantly increased (p<0.001) while IIEF-5 scores decreased and the SF-36 score did not change significantly. The rate of rectal fistulization and severe incontinence was 3.7% each. A total of 223 complications were recorded in the 180-days after HIFU (Clavien-Dindo grades 1=195, grade II= 20, grade III= 7, grade IVa=1).
Salvage HIFU appears to be a viable treatment option for rr-PCa, with acceptable morbidity.
The Journal of urology. 2016 Jul 12 [Epub ahead of print]
Khurram M Siddiqui, Michele Billia, Andrew Arifin, Fan Li, Philippe Violette, Joseph L Chin
Western University, London, Ontario, Canada., Western University, London, Ontario, Canada., Western University, London, Ontario, Canada., Western University, London, Ontario, Canada., Woodstock Hospital, Woodstock, Canada., Western University, London, Ontario, Canada.